Asset profile

pTau217 · Quanterix (QTRX)

Indication: neurological disease (Alzheimer’s disease, neurodegeneration, neuroinflammation)
Also known as: ALZpath pTau217, Simoa ALZpath pTau217 Assay, HD-X, SR-X, GFAP, p-Tau 181, NfL

Company

Quanterix Corp is a life sciences company accelerating biomarker breakthroughs from discovery to diagnostics using ultra-sensitive translational research and spatial biology instruments, consumables, and services. The company sells proprietary instruments and …

Start live analysis of QTRX Run 8-agent AI analysis

On the calendar

Nothing scheduled in this window.

Timeline

Newest first.

Oct 7, 2026

08:30 PM

QTRXQuanterix

Quanterix expands licensing agreement with ALZpath for pTau217 antibody

Partnership / licensing dealCompany press release Open record1 update

Readiness checklist

Public facts only. We never publish an approval probability.

Updated Oct 7, 2026

Primary endpoint metUnknown

Overall survival significant or trendingUnknown

US / Western patient shareUnknown

Advisory committee scheduledFavourable

No advisory committee announced

PDUFA date extendedUnknown

Manufacturing inspection recordUnknown

No public inspection record

Company language signals (label discussions)Unknown

Same-class precedentUnknown

Related companies

Each relationship is backed by the filing that stated it.

ALZpath, Inc. Not US-listedPartner

Innovita Biological Technology Co., Ltd. Not US-listedPartner

QTRXQuanterixOwner

Company press release Oct 7, 2026
Company press release Oct 7, 2026

Verify every date against the linked primary source. Informational only. Not investment advice. SimianX is not affiliated with the FDA or the SEC.